KalVista Pharmaceuticals

$15.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-2.01%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell KALV and other stocks, options, ETFs, and crypto commission-free!

About KALV

KalVista Pharmaceuticals, Inc. Common Stock, also called KalVista Pharmaceuticals, is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Read More Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

Employees
45
Headquarters
Cambridge, Massachusetts
Founded
Market Cap
271.08M
Price-Earnings Ratio
Dividend Yield
Average Volume
72.07K
High Today
$16.12
Low Today
$15.41
Open Price
$15.75
Volume
69.46K
52 Week High
$34.92
52 Week Low
$14.74

Collections

KALV Earnings

-$0.49
-$0.37
-$0.25
-$0.13
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
Actual
Expected Sep 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.